

DAFTAR PUSTAKA

- Agbabiaka, T.B., Savovi, J., Ernst, E. 2008. Methods for Causality Assessment of Adverse Drug Reactions A Systematic Review. *Drug Saf.*;31: 21-37.
- Agustina, J., Sinulingga, D., Suzanna, E., Andinata, B., Ramadhan, R., Kadir, A. 2018. Epidemiology of Female Breast Cancer in West Jakarta, Indonesia. *J Glob Oncol.* ; 4: S2, 65s-66s.
- Anampa, J. and Sparano, J. 2016. Tailoring Adjuvant Therapy for Breast Cancer in the Elderly: Room for Improvement. *Breast J.*, 23:253-5.
- Apisathanarax N. and Duvic M. 2003. Dermatologic complications of cancer chemotherapy, In: Frei Cancer Medicine, editor. BC Decker, Hamilton, London; p.2271-8.
- Aragues I.H., Rodriguez O.B., Vilas-Boas P.T., Montero E.C., Fernandez R.S. 2017 Cutaneous drug reactions : chemotherapy-induced hyperpigmentation. *EJD*; 27: 679-80.
- Azim, H.A., de Azambuja, E., Colozza, M., Bines, J., Piccart, M. J. 2011. Long-term toxic effects of adjuvant chemotherapy in breast cancer. *Ann Oncol.*; 22: 1939-47.
- Baker, A.F., Dorr, R.T. 2001. Drug Interactions with the taxanes : clinical implications. *Cancer Treat Rev* 27; 221-33.
- Batchelor, D. 2001. Hair and cancer chemotherapy: consequences and nursing care- a literature study. *Eur J Cancer Care*. 10 :147-163 .
- Bhattacharya G.S. 2010. Oral systemic therapy : Not all win-win. *Indian J Med Paediatr Oncol*; 31: 1-4.
- Bellent, K. 2011. Health Reference Series: Cancer Sourcebook. United States: Omnigraphic Inc.
- Biswal, S.G., Mehta, R.D. 2018. Cutaneous Adverse Reactions of Chemotherapy in Cancer Patients: A Clinicoepidemiological Study. *Indian J Dermatol.*; 63: 41-6.
- Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., *et al.* 2018. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). *Ann Oncol.*, 29:1634-57.
- Cherny, N.I., Dafni, U., Bogaerts, J. 2017. ESMO-Magnitude of Clinical Benefit Scale version 1.1. *Ann Oncol*; 28: 2340-66.

- Chun S.Y., Chang, S.N., Oh, D., Park, W.H. 2000. A case of cutaneous reaction to chemotherapeutic agents showing epidermal dysmaturation. *J Am Acad Dermatol.* ;43:358-60.
- Coates, A.S., Winer, A.P., Goldhirsch, A., Gelber, R.D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.J. & Panel Member. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Ann Oncol.*;26: 1533–46.
- Cutler, C. , Li, S., Kim, H.T., Laglenne, P., Szeto, K.C., Hoffmeister, L., *et al.* 2005. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. *Biol Blood Marrow Transplant.* 11:383-8.
- Dickel, H., Bruckner, T.M., Schmidt, A., Diepgen, A.L. 2003. Impact of Atopic Skin Diathesis on Occupational Skin Disease Incidence in a Working Population. *J Invest Dermatol.*;121:37-40.
- Diepgen, T.L., Sauerbrei, W., Furta, M. 1996. Development and Validation of Diagnostic Scores for Atopic Dermatitis Incorporating Criteria of Data Quality and Practical Usefulness. *J Clin Epidemiol.*;49:1031-8.
- Douillard, J.Y., Hoff, P.M., Skillings, J.R., Eisenberg, P., Davidson, R., Harper, P., *et al.* 2006. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* ;20:3605-16.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto, R., Davies, C., Godwin, J., *et al.* 2012. *Lancet.* 379:432.
- Fabbrocini, G., Cameli, N., Romano, M., Mariano, M., Panariello, L., Bianca, D. and Monfrecola, G. 2012. Chemotherapy and skin reactions. *JECCR*;31: 50.
- Fabbrocini, G., Izzo, R., Panariello, L., Monfrecola, G. 2013. Skin Reactions Secondary to Anticancer Obatts. *EMJ Dermatol.*;1:38-43.
- Frame, D. 2000. Introduction to taxane pharmacokinetics and pharmacodynamics. *J Oncol Pharm Pract.*; 6 :S23-S27.
- Galimont-Collen, A.F., Vos, L.E., Lavrijsen, A.P. 2007. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. *Eur J Cancer* 2007; 43: 845– 51.
- Gill, J., Dominguez, R.A. 2016. Cutaneous Manifestations of Chemotherapeutic Drugs. *Curr Derm Rep*;5:58–69.
- Gutzmer, R. 2012. Cutaneous side effects of new antitumor drugs: clinical features and management. *Dtsch Arztebl Int.*;109:133-40.

- Jatoi, A. and Nguyen, P. 2008. Do Patients Die from Rashes from Epidermal Growth Factor Receptor Inhibitors? A Systematic Review to Help Counsel Patients About Holding Therapy. *The Oncologist*; 13;1201-4.
- Johansson, S.G.O., Bieber, T., Dahl, R., Friedmann, P.S., Lanier, B.Q., Locley, R.F. 2004. Revised nomenclature for allergy for global use: report of the nomenclature review committee of the world allergy organization, October 2003. *J Allergy Clin Immunol.*;113:832-6.
- Kane-Gill, S.L., Kirisci L., Pathak, D.S. 2005. Are the Naranjo Criteria Reliable and Valid for Determination of Adverse Drug Reactions in the Intensive Care Unit? *Ann Pharmacother.*;39:1823-7.
- Kardaun, SH. 2008. Toxicodermie. *Ned Tijdschr Dermatol Venereol.*;18: 361.
- Kemenkes RI. Komite Penanggulangan Kanker Nasional. 2019. Panduan Penatalaksanaan Kanker Payudara. [cited 4 Apr. 2019]. Available from <http://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf>
- Kinoshita, T., Nakayama, T., Fukuma, E., Inokucchi, M., Ishiguro, H., Ogo, E., *et al.* 2019. Efficacy of Scalp Cooling in Preventing and Recovering from Chemotherapy-induced Alopecia in Breast Cancer Patient: The HOPE Study. *Front. Oncol*; 9:733.
- Kondov, B., Milenkovicj, Z., Kondov, G., Petrushevska,G., Basheska, N., Bogdanovska-Todorovska, M., *et al.* 2018. Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients. *OAMJMS*;6:961-7.
- Lacouture, M.E., Boerner, S.A., Lorusso, P.M. 2006. Non-rash skin toxicities associated with novel targeted therapies. *Clin Lung Cancer* ;8 Suppl 1:S36-42.
- Lacouture, M.E., Schadendorf, D., Chu, C.Y., *et al.* 2013. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. *Expert Rev. Anticancer Ther.*; 13, 721–8.
- Lau, C.P., Hui, P., Chan, T.C. 2011. Docetaxel-induced nail toxicity: a case of severe onycholysis and topic review. *Chin Med J (Engl)*;124:2559-60.
- Lemeshow, S. and David, J. 1997. Besar Sampel dalam Penelitian Kesehatan (terjemahan). Gadjah Mada University Press, Yogyakarta.
- Lynch, T.J, Kim, E.S., Eaby, B. *et al.* 2007. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. *The Oncologist* ;12:610–21.

- Malpas, J.S. and Rohatiner, A. 1996. Principles of cancer chemotherapy. In: *Advances in Oncobiology Volume 1*, editor. p. 317-50.
- Marsh, S. and Liu, G. 2009. Pharmacokinetics and pharmacodynamics in breast cancer chemotherapy. *Adv Drug Deliv Rev.* ;61: 381–7.
- Masuda, N., Lee, S.J., Ohtani, S., *et al.* 2017. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. *N Engl J Med*; 376:2147.
- Moore S. 2017. Managing treatment side effects in advanced breast cancer. *Semin Oncol Nurs.* 2007;23(4 Suppl 2):S23–S30.
- Mudigubba, M.K., Rajashekarachari, Y., Dahiya, S. 2017. Risk Factors Associated With Adverse Drug Reactions In Hospitalized Patients. *IJPSR*;8: 3847-54.
- Nagar, S. 2010. Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy. *Adv Exp Med Biol.* ;678:124-32.
- Narasimharao, R. and Mahatme, N. 2016. A study of clinical patterns and causative agents of adverse cutaneous drug reactions. *Indian J Drugs Dermatol.*; 2:13.
- National Cancer Institute. 2017. Protocol Development | CTEP. [cited 4 Apr. 2019]. Available from https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
- Nayak S., Acharia B. 2008. Adverse cutaneous drug reaction. *Indian J Dermatol.*; 53: 2–8.
- Negus, S.S and Banks, M.L. 2018. Pharmacokinetic—Pharmacodynamic (PKPD) Analysis with Drug Discrimination. *Curr Top Behav Neurosci.*; 39: 245–59.
- Oshiro, C., Marsh, S., McLeod, H. Carrillo, M. Klein, T. Altman, R. 2009. Taxane Pathway. *Pharmacogenet Genomics*; 19: 979–83.
- Pagan, J. 2019. *Algorithm Plots Efficient Course for Assessing Immune-related Adverse Events in Cancer Immunotherapy - Oncology Nurse Advisor.* [online] Oncology Nurse Advisor. Available from: <https://www.oncologynurseadvisor.com/home/headlines/conference-coverage/ons-annual-congress-2016/algorithm-plots-efficient-course-for-assessing-immune-related-adverse-events-in-cancer-immunotherapy/>.
- Paik₂ S₂, Tang₂ G₂, Shak₂ S₂, *et al.* 2006. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *J Clin Oncol.*; 24:3726.
- Palamaras, I., Misciali, C., Vincenzi, C., Roble, W.S., Tosti, A. 2011. Permanent chemotherapy-induced alopecia: A review. *J Am Acad Dermatol.*;64:604-6.

- Pan, Y., Zhang, F., Yawei, Z., Shao, D., Zheng, X., Chen, Y., *et al.* 2017. Berberine Enhances Chemosensitivity and Induces Apoptosis Through Dose-orchestrated AMPK Signaling in Breast Cancer. *J. Cancer*; 8: 1679-89.
- Paus, R., Haslam, I.S., Sharov, A.A. 2013. Pathobiology of chemotherapy-induced hair loss. *Lancet Oncol*;14:e50–9.
- Pichler, W.J. 2003. Delayed drug hypersensitivity reactions. *Ann. Intern. Med.*; 139, 683-93.
- Prat, A., Adamo, B., Cheang, M., Anders, C., Carey, L. and Perou, C. (2013). Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer. *The Oncologist*; 18:123-33.
- Prevezas, C., Matard, B., Pinquier, L., *et al.* 2009. Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer. *Br J Dermatol.*;160:883-5
- Raut, A.L., Patel, P., Patel, C., Pawar, A. 2012. Preventability, predictability and seriousness of adverse drug reactions amongst medicine inpatients in a teaching hospital: a prospective observational study. *IJPCS*; 1:944-50.
- Reyes-Habito, C. and Roh, E. 2014. Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer. *J Am Acad Dermatol.*;71:203.e1-203.e12.
- Rosen, A., Amitay-Laish, I., Lacouture, M. Management algorithms for dermatologic adverse events. 2014. In: Lacouture ME, editor. *Dermatologic principles and practice in oncology: conditions of the skin, hair and nails in cancer patients*. 1st ed. Philadelphia (PA): Wiley-Blackwell; 367-83.
- Russi, E.G., Raber-Durlacher, J.E, Sonis, S.T. 2014. Local and systemic pathogenesis and consequences of regimen-induced inflammatory responses in patients with head and neck cancer receiving chemoradiation. *Mediators Inflamm.*;5:18-26.
- Scotté, F., Tourani, J.M., Banu, E., Peyromaure, M., Levy, E., Marsan, S. 2005. Multicenter study of a frozen glove to prevent docetaxel induced onycholysis and cutaneous toxicity of the hand. *JCO*;23:4424–9.
- Segaert, S., Tabernero, J., Chosidow, O., Dirschka, T., Elsner, J., Mancini, L., *et al.* 2005. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. *Behandlung der Hautreaktionen bei EGFR-spezifischer Tumorthherapie (Epidermaler Wachstumsfaktor Rezeptor)*. *JDDG*; 3:599-606.
- Segaert, S., van Cutsem, E. 2005. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. *Ann Oncol.*;16:1425–33.

- Shajahan, J., Pillai, P.S., Jayakumar, K.N. 2015. A Prospective Comparative Study of the Toxicity Profile of 5-Fluorouracil, Adriamycin, Cyclophosphamide Regime VS Adriamycin, Paclitaxel Regime in Patients with Locally Advanced Breast Carcinoma. *J Clin Diagn Res.* (12):FC01-6.
- Shiozawa, T., Tadokoro, J., Fujiki, T., Fujino, K., Kakihata, K., Masatani, S., *et al.* 2013. Risk Factors for Severe Adverse Effects and Treatment-related Deaths in Japanese Patients Treated with Irinotecan-based Chemotherapy: A Postmarketing Survey. *Jpn J Clin Oncol*; 43:483-91.
- Siegel, R.L., Miller, K.D., Jemal, A. 2018. Cancer Statistics, 2018. *CA Cancer J Clin.* ;68:7-30.
- Singh, J.C., Lichtman, S.M. 2015. Effect of obat on drug metabolism in women eith breast cancer. *Expert Opin Drug Metab Toxicol.*; 11: 757-66.
- Skacel, T., von Moos, R., Dummer, R. 2014. Topoisomerase-interacting obatts. In: Lacouture ME, editor. *Dermatologic principles and practice in oncology: conditions of the skin, hair and nails in cancer patients.* 1st ed. Philadelphia (PA): Wiley-Blackwell; 170-83.
- Solimando, D.A. 2004. Drug information handbook for oncology. Lexi-Comp: Ohio; p. 234-40.
- Sonis, S.T. 2004. The pathobiology of mucositis. *Nat Rev Cancer* ;4:277.
- Swain, S.M., Kim, S.B., Corte, s.J. 2013. Pertuzumab, trastuzumab, and doce-taxel for HER2-positive metastatic breast cancer (CLEOPATRA study):overall survival results from a randomised, double-blind, placebo-con-trolled, phase 3 study. *Lancet Oncol.*;14: 461–71.
- Tallon, B., Blanchard, E., Goldberg, L.J., *et al.* 2010. Permanent chemotherapy-induced alopecia: case report and review of the literature. *J Am Acad Dermatol*, 63:333-6.
- Toffoli, G.,Corona,G., Basso, B., Boiocchi, M. 2004. Pharmacokinetic optimization of treatment with oral etoposide. *Clin Pharmacokinet.* ;43:441-66.
- Tanzania Food and Drugs Authority. 2006. Guidelines for Monitoring and Reporting Adverse Drug Events (ADRs). Apps.who.int. [online] Available at: <http://apps.who.int/medicinedocs/documents/s18571en/s18571en.pdf>
- Wilkes G. M. 1996. Potential toxicities and nursing management, In: *Cancer Chemotherapy: Nursing Process Approach.* Jones & Bartlet, Boston; p.130-5.
- Wright, L.G. 2006. Maculopapular Skin Rashes Associated with High-Dose Chemotherapy : Prevalence and Risk Factors. *ONF* ;33 :1095-103.
- Zhang, L., Zhou, Q., Ma, L. 2011. Meta-analysis of dermatological toxicities associated with sorafenib. *Clin Exp Dermatol*; 36:344.